Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial

Table 3 Multivariate regression analysis of independent determinants for being Responders^T13

	aOR = Exp(B)	SE	Wald χ²	95% confidence interval	p value
Age (years)	0.97	0.03	0.84	0.92–1.0	0.360
Sex	3.6	0.68	3.6	0.96–13.6	0.058
MIDAS^Res	2.1	0.56	1.8	0.70–6.3	0.185
MMD^Res	7.1	0.58	11.3	2.3–22.4	0.001

Legend: aOR: adjusted Odds Ratio; MIDAS^Res: Patients with a MIDAS reduction of at least 50% at T3. MMD^Res: Patients with MMDs reduction of at least 50% at T3. +T3: follow-up visit at three months after first erenumab administration. Variables tested but not included in the final model according to a stepwise analysis: baseline general health score, baseline HADS-D score, days of acute drug intake at baseline, and use of preventive treatment at baseline

ISSN: 1129-2377